Promising Phase 2 Trial Results Boost Confidence in PDS Biotechnology’s Versamune HPV for Advanced Head and Neck Cancer

In a report released today, Joseph Pantginis from H.C. Wainwright reiterated a Buy rating on PDS Biotechnology (PDSB – Research Report), with a price target of $13.00.

Joseph Pantginis has given his Buy rating due to a combination of factors including the promising results from PDS Biotechnology’s VERSATILE-002 trial. The updated data presented at ASCO 2025 demonstrated the potential of Versamune HPV in combination with pembrolizumab as a first-line treatment for advanced HPV16+ head and neck squamous cell carcinoma. The trial showed a median overall survival of 30 months, which is significantly higher than the typical outcomes for this patient population.
The objective response rate of 35.8% and the absence of new safety signals further support the positive clinical profile of the treatment. Compared to current standard-of-care therapies, which offer median overall survival of around 18 months, the Versamune HPV/pembrolizumab combination shows superior clinical activity and durability. These encouraging results position Versamune HPV favorably for the ongoing Phase 3 VERSATILE-003 trial, reinforcing Pantginis’s confidence in the stock’s potential growth.